Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis

References

• Castejón M, Plaza A, Martinez-Romero J, Fernandez-Marcos PJ, Cabo R, Diaz-Ruiz A. Energy restriction and colorectal cancer: a call for additional research. Nutrients. 2020;12(1):114. doi:10.3390/nu12010114
   PubMed Web of Science ®Google Scholar
• Sun JJ, Fan GL, Wang XG, Xu K. The research on the influences of hyperthermal perfusion chemotherapy combined with immunologic therapy on the immunologic function and levels of circulating tumor cells of the advanced colorectal cancer patients with liver metastasis. Eur Rev Med Pharmacol Sci. 2017;21(13):3139–3145.28742190
   PubMed Web of Science ®Google Scholar
• Donadon M, Cortese N, Marchesi F, Cimino M, Mantovani A, Torzilli G. Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients. Hepatobiliary Surg Nutr. 2019;8(4):370–377. doi:10.21037/hbsn.2019.03.0631489306
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Morise Z, Tanaka C, et al. Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study. World J Surg Oncol. 2019;17(1):33. doi:10.1186/s12957-019-1575-y30770753
   PubMedGoogle Scholar
• Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–4580. doi:10.1200/JCO.2007.11.083317925551
   PubMed Web of Science ®Google Scholar
• Dendy MS, Ludwig JM, Kim HS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget. 2017;8(23):37912–37922. doi:10.18632/oncotarget.1600728415671
   PubMedGoogle Scholar
• Qian Y, Zeng ZC, Ji Y, Xiao YP. Microinvasion of liver metastases from colorectal cancer: predictive factors and application for determining clinical target volume. Radiat Oncol. 2015;10(1). doi:10.1186/s13014-015-0428-2
   PubMedGoogle Scholar
• Wang Y, Zheng J, Chen H, et al. A prognostic nomogram for colorectal cancer liver metastases after percutaneous thermal ablation. Int J Hyperthermia. 2018;34(6):853–862. doi:10.1080/02656736.2017.136809528826279
   PubMed Web of Science ®Google Scholar
• Wang C, Park J, Ouyang C, et al. A pilot feasibility study of yttrium-90 liver radioembolization followed by durvalumab and tremelimumab in patients with microsatellite stable colorectal cancer liver metastases. Oncologist. 2020;25(5):382–e776. doi:10.1634/theoncologist.2019-092431857446
   PubMed Web of Science ®Google Scholar
• Xiong YX, Ren L, Wang ZQ, Huang XW, Zhou YJ. The role of angiogenesis inhibitors re-challenge in colorectal cancer previously treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2017;21(7):1489–1494.28429359
   PubMed Web of Science ®Google Scholar
• Arnold D, Prager GW, Quintela A, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol. 2018;29(4):835–856. doi:10.1093/annonc/mdy03829452346
   PubMed Web of Science ®Google Scholar
• Naito A, Kagawa Y, Kawai K, et al. Surgical resection of colorectal cancer with distant metastases to other than liver or lung. In Vivo (Athens, Greece). 2019;33(5):1605–1608.
   PubMed Web of Science ®Google Scholar
• Tai D, Choo SP, Chew V. Rationale of immunotherapy in hepatocellular carcinoma and its potential biomarkers. Cancers. 2019;11(12):1926. doi:10.3390/cancers11121926
   PubMed Web of Science ®Google Scholar
• Koi M, Carethers JM. The colorectal cancer immune microenvironment and approach to immunotherapies. Future Oncol. 2017;13(18):1633–1647. doi:10.2217/fon-2017-014528829193
   PubMed Web of Science ®Google Scholar
• Lingling Z, Jiewei L, Li W, et al. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathol Res Pract. 2020;216(4):152852. doi:10.1016/j.prp.2020.15285232057515
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SY, Baek JY, et al. A phase II study of avelumab monotherapy in patients with mismatch repair-deficient/microsatellite instability-high or pole-mutated metastatic or unresectable colorectal cancer. Cancer Res Treat. 2020. doi:10.4143/crt.2020.218
   Web of Science ®Google Scholar
• Richman S. Deficient mismatch repair: read all about it (review). Int J Oncol. 2015;47(4):1189–1202. doi:10.3892/ijo.2015.311926315971
   PubMed Web of Science ®Google Scholar
• Germano G, Amirouchene-Angelozzi N, Rospo G, Bardelli A. The clinical impact of the genomic landscape of mismatch repair-deficient cancers. Cancer Discov. 2018;8(12):1518–1528. doi:10.1158/2159-8290.CD-18-015030442708
   PubMed Web of Science ®Google Scholar
• Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D. Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer. Cancers. 2019;11(10):1567. doi:10.3390/cancers11101567
   PubMed Web of Science ®Google Scholar
• Franke AJ, Skelton WP, Starr JS, et al. Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches. J Natl Cancer Inst. 2019;111(11):1131–1141. doi:10.1093/jnci/djz09331322663
   PubMedGoogle Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576. doi:10.1038/s41591-020-0805-832251400
   PubMed Web of Science ®Google Scholar
• Hamada T, Zhang X, Mima K, et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol Res. 2018;6(11):1327–1336. doi:10.1158/2326-6066.CIR-18-017430228205
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.2929508855
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.29686425
   PubMed Web of Science ®Google Scholar
• Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11(369). doi:10.3389/fimmu.2020.00369
   Google Scholar
• Burr ML, Sparbier CE, Chan KL, et al. An evolutionarily conserved function of polycomb silences the MHC class i antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36(4):385–401.e388. doi:10.1016/j.ccell.2019.08.00831564637
   PubMed Web of Science ®Google Scholar
• Gang W, Wang JJ, Guan R, et al. Strategy to targeting the immune resistance and novel therapy in colorectal cancer. Cancer Med. 2018;7(5):1578–1603. doi:10.1002/cam4.138629658188
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol. 2016;13(12):691–706. doi:10.1038/nrgastro.2016.16527848961
   PubMed Web of Science ®Google Scholar
• Kim TM, Jung SH, An CH, et al. Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity. Clin Cancer Res. 2015;21(19):4461–4472. doi:10.1158/1078-0432.CCR-14-241325979483
   PubMed Web of Science ®Google Scholar
• Pancione M, Giordano G, Remo A, et al. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. J Immunol Res. 2014;2014:686879. doi:10.1155/2014/68687924741617
   PubMed Web of Science ®Google Scholar
• Gessani S, Belardelli F. Immune dysfunctions and immunotherapy in colorectal cancer: the role of dendritic cells. Cancers. 2019;11(10):1491. doi:10.3390/cancers11101491
   PubMed Web of Science ®Google Scholar
• Wu JB, Sarmiento AL, Fiset PO, et al. Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis. World J Gastroenterol. 2019;25(26):3408–3425. doi:10.3748/wjg.v25.i26.340831341365
   PubMed Web of Science ®Google Scholar
• Höppener DJ, Nierop PMH, Herpel E, et al. Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy. Clin Exp Metastasis. 2019;36(4):311–319. doi:10.1007/s10585-019-09975-031134394
   PubMed Web of Science ®Google Scholar
• Galjart B, Nierop PMH, van der Stok EP, et al. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis. 2019;22(2):355–368. doi:10.1007/s10456-019-09661-530637550
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tan X, Luo J, et al. GNA13 promotes tumor growth and angiogenesis by upregulating CXC chemokines via the NF-κB signaling pathway in colorectal cancer cells. Cancer Med. 2018;7(11):5611–5620. doi:10.1002/cam4.178330267476
   PubMed Web of Science ®Google Scholar
• Tsoumas D, Nikou S, Giannopoulou E, et al. ILK expression in colorectal cancer is associated with EMT, cancer stem cell markers and chemoresistance. Cancer Genomics Proteomics. 2018;15(2):127–141.29496692
   PubMed Web of Science ®Google Scholar
• Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune checkpoint modulation in colorectal cancer: what’s new and what to expect. J Immunol Res. 2015;2015:158038. doi:10.1155/2015/15803826605342
   PubMed Web of Science ®Google Scholar
• Cortese N, Soldani C, Franceschini B, et al. Macrophages in colorectal cancer liver metastases. Cancers. 2019;11(5):633. doi:10.3390/cancers11050633
   PubMed Web of Science ®Google Scholar
• Iseki Y, Shibutani M, Maeda K, et al. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS One. 2018;13(4):e0192744.29698402
   PubMed Web of Science ®Google Scholar
• Shibutani M, Maeda K, Nagahara H, et al. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. BMC Cancer. 2018;18(1):371. doi:10.1186/s12885-018-4276-y29614981
   PubMedGoogle Scholar
• Fletcher R, Wang YJ, Schoen RE, Finn OJ, Yu J, Zhang L. Colorectal cancer prevention: immune modulation taking the stage. Biochim Biophys Acta Rev Cancer. 2018;1869(2):138–148. doi:10.1016/j.bbcan.2017.12.00229391185
   PubMed Web of Science ®Google Scholar
• Zeng Z, Li Y, Pan Y, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9(1):5395. doi:10.1038/s41467-018-07810-w30568162
   PubMed Web of Science ®Google Scholar
• Guo Y, Ji X, Liu J, et al. Effects of exosomes on pre-metastatic niche formation in tumors. Mol Cancer. 2019;18(1):39. doi:10.1186/s12943-019-0995-130857545
   PubMed Web of Science ®Google Scholar
• Balacescu O, Sur D, Cainap C, et al. The impact of miRNA in colorectal cancer progression and its liver metastases. Int J Mol Sci. 2018;19(12):3711. doi:10.3390/ijms19123711
   PubMed Web of Science ®Google Scholar
• Herrera M, Galindo-Pumariño C, García-Barberán V, Peña C. A snapshot of the tumor microenvironment in colorectal cancer: the liquid biopsy. Int J Mol Sci. 2019;20(23):6016. doi:10.3390/ijms20236016
   PubMed Web of Science ®Google Scholar
• Koliarakis I, Psaroulaki A, Nikolouzakis TK, et al. Intestinal microbiota and colorectal cancer: a new aspect of research. J BUON. 2018;23(5):1216–1234.30512251
   PubMed Web of Science ®Google Scholar
• Kather JN, Charoentong P, Suarez-Carmona M, et al. High-throughput screening of combinatorial immunotherapies with patient-specific in silico models of metastatic colorectal cancer. Cancer Res. 2018;78(17):5155–5163. doi:10.1158/0008-5472.CAN-18-112629967263
   PubMed Web of Science ®Google Scholar
• Lazarus J, Maj T, Smith JJ, et al. Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight. 2018;3(22). doi:10.1172/jci.insight.121932.
   PubMed Web of Science ®Google Scholar
• Toor SM, Murshed K, Al-Dhaheri M, Khawar M, Abu NM, Elkord E. Immune checkpoints in circulating and tumor-infiltrating CD4(+) T cell subsets in colorectal cancer patients. Front Immunol. 2019;10:2936.31921188
   PubMed Web of Science ®Google Scholar
• Germann M, Zangger N, Sauvain MO, et al. Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFbeta. EMBO Mol Med. 2020;12(1):e10681. doi:10.15252/emmm.20191068131793740
   PubMed Web of Science ®Google Scholar
• Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–318. doi:10.1016/j.biopha.2018.11.10530522017
   PubMed Web of Science ®Google Scholar
• Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Semin Cancer Biol. 2018;52(Pt 2):189–197. doi:10.1016/j.semcancer.2018.02.01029501787
   PubMedGoogle Scholar
• Bestvina CM, Vokes E. Correction to lancet oncol 2017. Lancet Oncol. 2017;18(9):510.28884691
   PubMedGoogle Scholar
• Sun X, Suo J, Yan J. Immunotherapy in human colorectal cancer: challenges and prospective. World J Gastroenterol. 2016;22(28):6362–6372. doi:10.3748/wjg.v22.i28.636227605872
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153–162. doi:10.1038/nrclinonc.2009.23720142816
   PubMed Web of Science ®Google Scholar
• Baek SK, Lee KT, Bae SB, Lee SC. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean J Intern Med. 2019;34(6):1188–1196. doi:10.3904/kjim.2019.07131346151
   PubMed Web of Science ®Google Scholar
• Wang J, Zhen W, Kang X. Pseudo progression in heterogeneity of right-sided metastatic colon carcinoma during nivolumab therapy: a case report. Medicine. 2019;98(32):e16490. doi:10.1097/MD.000000000001649031393352
   PubMed Web of Science ®Google Scholar
• Ronnekleiv-Kelly SM, Burkhart RA, Pawlik TM. Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surg Oncol. 2016;25(3):190–199. doi:10.1016/j.suronc.2016.05.01827566022
   PubMed Web of Science ®Google Scholar
• Nosho K, Sukawa Y, Adachi Y, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol. 2016;22(2):557–566. doi:10.3748/wjg.v22.i2.55726811607
   PubMed Web of Science ®Google Scholar
• Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: a review. J Surg Oncol. 2006;94(1):68–80. doi:10.1002/jso.2055816788948
   PubMed Web of Science ®Google Scholar
• Clark AM, Ma B, Taylor DL, Griffith L, Wells A. Liver metastases: microenvironments and ex-vivo models. Exp Biol Med (Maywood). 2016;241(15):1639–1652.27390264
   PubMed Web of Science ®Google Scholar
• Walkowska J, Kallemose T, Andersen MH, Andersen O, Therkildsen C, Langkilde A. Immunoprofiles of colorectal cancer from Lynch syndrome. Oncoimmunology. 2019;8(1):e1515612. doi:10.1080/2162402X.2018.151561230546958
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):8. doi:10.1186/s13045-017-0552-629329556
   PubMed Web of Science ®Google Scholar
• Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11(1):97–119.28085225
   PubMed Web of Science ®Google Scholar
• Janiczek M, Szylberg Ł, Kasperska A, et al. Immunotherapy as a promising treatment for prostate cancer: a systematic review. J Immunol Res. 2017;2017:4861570. doi:10.1155/2017/486157029109964
   PubMed Web of Science ®Google Scholar
• Mercier J, Voutsadakis IA. The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer. J Gastrointest Oncol. 2018;9(3):478–486. doi:10.21037/jgo.2018.03.1329998013
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.000000000000023926558876
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lee CK, Lin CH, et al. PD-L1: CD80Cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. Immunity. 2019;51(6):1059–1073.e1059. doi:10.1016/j.immuni.2019.11.00331757674
   PubMed Web of Science ®Google Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255. doi:10.1186/s13046-019-1259-z31196207
   PubMed Web of Science ®Google Scholar
• Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun. 2019;39(1):13. doi:10.1186/s40880-019-0361-0
   Web of Science ®Google Scholar
• Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67.29118008
   PubMed Web of Science ®Google Scholar
• Fiegle E, Doleschel D, Koletnik S, et al. Dual CTLA-4 and PD-L1 blockade inhibits tumor growth and liver metastasis in a highly aggressive orthotopic mouse model of colon cancer. Neoplasia. 2019;21(9):932–944. doi:10.1016/j.neo.2019.07.00631412307
   PubMed Web of Science ®Google Scholar
• Sasidharan NV, Toor SM, Taha RZ, Shaath H, Elkord E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin Epigenetics. 2018;10(1):104. doi:10.1186/s13148-018-0539-330081950
   PubMedGoogle Scholar
• Joller N, Kuchroo VK. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol. 2017;410:127–156.28900677
   PubMed Web of Science ®Google Scholar
• Sasidharan NV, Toor SM, Taha RZ, et al. Transcriptomic profiling of tumor-infiltrating CD4(+)TIM-3(+) T cells reveals their suppressive, exhausted, and metastatic characteristics in colorectal cancer patients. Vaccines. 2020;8(1).
   Web of Science ®Google Scholar
• Kuai W, Xu X, Yan J, et al. Prognostic impact of PD-1 and Tim-3 expression in tumor tissue in stage I-III colorectal cancer. Biomed Res Int. 2020;2020:5294043. doi:10.1155/2020/529404332509862
   PubMed Web of Science ®Google Scholar
• Wang W, Chen D, Zhao Y, et al. Characterization of LAG-3, CTLA-4, and CD8(+) TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma. Ann Transl Med. 2019;7(23):776. doi:10.21037/atm.2019.11.3832042792
   PubMed Web of Science ®Google Scholar
• Lecocq Q, Zeven K, De VY, et al. Noninvasive imaging of the immune checkpoint LAG-3 using nanobodies, from development to pre-clinical use. Biomolecules. 2019;9(10):548. doi:10.3390/biom9100548
   PubMed Web of Science ®Google Scholar
• Zeng H, Zhou Q, Wang Z, et al. Stromal LAG-3+ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. J Immunother Cancer. 2020;8(1):e000651. doi:10.1136/jitc-2020-00065132540859
   PubMed Web of Science ®Google Scholar
• Gestermann N, Saugy D, Martignier C, et al. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures. Oncoimmunology. 2020;9(1):1736792. doi:10.1080/2162402X.2020.173679232850194
   PubMed Web of Science ®Google Scholar
• Reches A, Ophir Y, Stein N, et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer. 2020;8(1):e000266. doi:10.1136/jitc-2019-00026632503945
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:10.1016/j.immuni.2016.05.00127192565
   PubMed Web of Science ®Google Scholar
• Jin HS, Choi DS, Ko M, et al. Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy. J Control Release. 2019;315:65–75. doi:10.1016/j.jconrel.2019.10.04131669264
   PubMed Web of Science ®Google Scholar
• Lupo KB, Matosevic S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. J Hematol Oncol. 2020;13(1):76. doi:10.1186/s13045-020-00913-232532329
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.31690319
   PubMed Web of Science ®Google Scholar
• Busch DH, Fräßle SP, Sommermeyer D, Buchholz VR, Riddell SR. Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol. 2016;28(1):28–34. doi:10.1016/j.smim.2016.02.00126976826
   PubMed Web of Science ®Google Scholar
• Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20(6):1283. doi:10.3390/ijms20061283
   PubMed Web of Science ®Google Scholar
• Parkhurst M, Gros A, Pasetto A, et al. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin Cancer Res. 2017;23(10):2491–2505. doi:10.1158/1078-0432.CCR-16-268027827318
   PubMed Web of Science ®Google Scholar
• Jiang X, Xu J, Liu M, et al. Adoptive CD8(+) T cell therapy against cancer: challenges and opportunities. Cancer Lett. 2019;462:23–32. doi:10.1016/j.canlet.2019.07.01731356845
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.29344893
   PubMedGoogle Scholar
• Shitaoka K, Hamana H, Kishi H, et al. Identification of tumoricidal TCRs from tumor-infiltrating lymphocytes by single-cell analysis. Cancer Immunol Res. 2018;6(4):378–388. doi:10.1158/2326-6066.CIR-17-048929475880
   PubMed Web of Science ®Google Scholar
• Ollé HM, Wolbert J, Fisher J, et al. Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. PLoS One. 2019;14(8):e0216373. doi:10.1371/journal.pone.021637331398192
   PubMed Web of Science ®Google Scholar
• Lucas C, Barnich N, Nguyen HTT. Microbiota, Inflammation and colorectal cancer. Int J Mol Sci. 2017;18(6).
   Web of Science ®Google Scholar
• Boyiadzis MM, Dhodapkar MV, Brentjens RJ, et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018;6(1):137. doi:10.1186/s40425-018-0460-530514386
   PubMed Web of Science ®Google Scholar
• Yu S, Yi M, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer Ther. 2019;18(1):125.
   Google Scholar
• Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173(6):1426–1438.e1411. doi:10.1016/j.cell.2018.03.03829706540
   PubMed Web of Science ®Google Scholar
• Yu S, Yi M, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18(1):125. doi:10.1186/s12943-019-1057-431429760
   PubMed Web of Science ®Google Scholar
• Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–s9. doi:10.1002/ajh.25418
   PubMed Web of Science ®Google Scholar
• Teng R, Zhao J, Zhao Y, et al. Chimeric antigen receptor-modified T cells repressed solid tumors and their relapse in an established patient-derived colon carcinoma xenograft model. J Immunother. 2019;42(2):33–42.30586347
   PubMed Web of Science ®Google Scholar
• Sur D, Havasi A, Cainap C, et al. Chimeric antigen receptor T-cell therapy for colorectal cancer. J Clin Med. 2020;9(1):182. doi:10.3390/jcm9010182
   PubMed Web of Science ®Google Scholar
• Simmons A, Whitehead RP, Kolokoltsov AA, Davey RA. Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. Virol J. 2006;3(1):8. doi:10.1186/1743-422X-3-816507098
   PubMedGoogle Scholar
• Hege KM, Bergsland EK, Fisher GA, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5:22.28344808
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Z, Yang Z, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther. 2017;25(5):1248–1258. doi:10.1016/j.ymthe.2017.03.01028366766
   PubMed Web of Science ®Google Scholar
• Pagano F, Bassi P, Milani C, Piazza N, Meneghini A, Garbeglio A. BCG in superficial bladder cancer: a review of Phase III European trials. Eur Urol. 1992;21(Suppl 2):7–11. doi:10.1159/0004749141396947
   PubMed Web of Science ®Google Scholar
• Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol. 2016;28(7):329–338. doi:10.1093/intimm/dxw01527006304
   PubMed Web of Science ®Google Scholar
• Sarvizadeh M, Ghasemi F, Tavakoli F, et al. Vaccines for colorectal cancer: an update. J Cell Biochem. 2019;120(6):8815–8828. doi:10.1002/jcb.2817930536960
   PubMed Web of Science ®Google Scholar
• Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22(4):807–812. doi:10.1158/1078-0432.CCR-14-317526515495
   PubMed Web of Science ®Google Scholar
• Singh M, Ramos I, Asafu-Adjei D, et al. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med. 2013;2(4):571–582. doi:10.1002/cam4.9424156030
   PubMed Web of Science ®Google Scholar
• Sillo TO, Beggs AD, Morton DG, Middleton G. Mechanisms of immunogenicity in colorectal cancer. Br J Surg. 2019;106(10):1283–1297. doi:10.1002/bjs.1120431216061
   PubMed Web of Science ®Google Scholar
• Keirsse J, Van DH, Geeraerts X, Beschin A, Raes G, Van GJA. The role of hepatic macrophages in liver metastasis. Cell Immunol. 2018;330:202–215. doi:10.1016/j.cellimm.2018.03.01029661474
   PubMed Web of Science ®Google Scholar
• Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett. 2016;370(1):85–90. doi:10.1016/j.canlet.2015.10.00926477683
   PubMed Web of Science ®Google Scholar
• Lu C, Rong D, Zhang B, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18(1):130.31464625
   PubMed Web of Science ®Google Scholar
• Reha J, Katz SC. Regional immunotherapy for liver and peritoneal metastases. J Surg Oncol. 2017;116(1):46–54. doi:10.1002/jso.2464128543176
   PubMed Web of Science ®Google Scholar
• Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):396.31500650
   PubMed Web of Science ®Google Scholar
• Ge P, Wang W, Li L, et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomed Pharmacother. 2019;118:109228. doi:10.1016/j.biopha.2019.10922831351430
   PubMed Web of Science ®Google Scholar
• Van den Eynde M, Mlecnik B, Bindea G, et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. Cancer Cell. 2018;34(6):1012–1026 e1013. doi:10.1016/j.ccell.2018.11.00330537506
   PubMed Web of Science ®Google Scholar
• Zhou R, Zeng D, Zhang J, et al. A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer. EBioMedicine. 2019;42:420–430. doi:10.1016/j.ebiom.2019.03.04330917936
   PubMed Web of Science ®Google Scholar
• Hamada T, Nowak JA, Masugi Y, et al. Smoking and risk of colorectal cancer sub-classified by tumor-infiltrating T cells. J Natl Cancer Inst. 2019;111(1):42–51. doi:10.1093/jnci/djy13730312431
   PubMedGoogle Scholar
• Kurebayashi Y, Kubota N, Sakamoto M. Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: relationship with histopathological and molecular classifications. Hepatol Res. 2020. doi:10.1111/hepr.13539
   Web of Science ®Google Scholar
• Khazali AS, Clark AM, Wells A. A pathway to personalizing therapy for metastases using liver-on-a-chip platforms. Stem Cell Rev Rep. 2017;13(3):364–380.28425064
   PubMed Web of Science ®Google Scholar
• Jun HY, Lee YH, Juhng SK, Lee MS, Oh J, Yoon KH. Micro-CT measurements of tumoral vessels supplied by portal circulation in hepatic colorectal metastasis mouse model. Microsc Res Tech. 2014;77(6):415–421. doi:10.1002/jemt.2236124659362
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–1492. doi:10.1093/annonc/mdw16827069014
   PubMed Web of Science ®Google Scholar
• Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017;16(1):31. doi:10.1186/s12943-017-0597-828148268
   PubMed Web of Science ®Google Scholar
• Shiraha H, Iwamuro M, Okada H. Hepatic stellate cells in liver tumor. Adv Exp Med Biol. 2020;1234:43–56.32040854
   PubMed Web of Science ®Google Scholar
• Lei H, Reinke P, Volk HD, Lv Y, Wu R. Mechanisms of immune tolerance in liver transplantation-crosstalk between alloreactive T cells and liver cells with therapeutic prospects. Front Immunol. 2019;10:2667. doi:10.3389/fimmu.2019.0266731803188
   PubMed Web of Science ®Google Scholar
• Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer. 2019;7(1):333. doi:10.1186/s40425-019-0824-531783782
   PubMed Web of Science ®Google Scholar
• He Y, Dang Q, Li J, et al. Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set. Aging. 2020;12(1):965–977. doi:10.18632/aging.10266931929113
   PubMedGoogle Scholar
• Soydemir S, Comella O, Abdelmottaleb D, Pritchett J. Does mechanocrine signaling by liver sinusoidal endothelial cells offer new opportunities for the development of anti-fibrotics? Front Med. 2020;6:312. doi:10.3389/fmed.2019.00312
   Web of Science ®Google Scholar
• Wohlleber D, Knolle PA. The role of liver sinusoidal cells in local hepatic immune surveillance. Clin Transl Immunology. 2016;5(12):e117. doi:10.1038/cti.2016.74
   PubMed Web of Science ®Google Scholar
• Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology. 2014;60(5):1776–1782. doi:10.1002/hep.2724624912948
   PubMed Web of Science ®Google Scholar
• Yagiz K, Rodriguez-Aguirre ME, Lopez EF, et al. A retroviral replicating vector encoding cytosine deaminase and 5-FC induces immune memory in metastatic colorectal cancer models. Mol Ther Oncolytics. 2018;8:14–26. doi:10.1016/j.omto.2017.12.00129322091
   PubMed Web of Science ®Google Scholar
• Kimura Y, Inoue A, Hangai S, et al. The innate immune receptor Dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis. Proc Natl Acad Sci U S A. 2016;113(49):14097–14102. doi:10.1073/pnas.161790311327872290
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416.28117416
   PubMed Web of Science ®Google Scholar
• Timmers M, Vekemans K, Vermijlen D, et al. Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis. Int J Cancer. 2004;112(5):793–802. doi:10.1002/ijc.2048115386374
   PubMed Web of Science ®Google Scholar
• Itatani Y, Kawada K, Inamoto S, et al. The role of chemokines in promoting colorectal cancer invasion/metastasis. Int J Mol Sci. 2016;17(5):643. doi:10.3390/ijms17050643
   PubMed Web of Science ®Google Scholar
• Katz SC, Burga RA, McCormack E, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21(14):3149–3159. doi:10.1158/1078-0432.CCR-14-142125850950
   PubMed Web of Science ®Google Scholar
• Al BMH, Kim NK. Current status and future perspectives on treatment of liver metastasis in colorectal cancer (review). Oncol Rep. 2017;37(5):2553–2564. doi:10.3892/or.2017.553128350137
   PubMed Web of Science ®Google Scholar
• Milette S, Sicklick JK, Lowy AM, Brodt P. Molecular pathways: targeting the microenvironment of liver metastases. Clin Cancer Res. 2017;23(21):6390–6399. doi:10.1158/1078-0432.CCR-15-163628615370
   PubMed Web of Science ®Google Scholar
• Medina-Echeverz J, Eggert T, Han M, Greten TF. Hepatic myeloid-derived suppressor cells in cancer. Cancer Immunol Immunother. 2015;64(8):931–940. doi:10.1007/s00262-015-1736-y26133122
   PubMed Web of Science ®Google Scholar
• Zarour LR, Anand S, Billingsley KG, et al. Colorectal cancer liver metastasis: evolving paradigms and future directions. Cell Mol Gastroenterol Hepatol. 2017;3(2):163–173. doi:10.1016/j.jcmgh.2017.01.00628275683
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Bekaii-Saab T. A comprehensive review of sequencing and combination strategies of targeted agents in metastatic colorectal cancer. Oncologist. 2018;23(1):25–34. doi:10.1634/theoncologist.2017-020329021377
   PubMed Web of Science ®Google Scholar
• Martini G, Troiani T, Cardone C, et al. Present and future of metastatic colorectal cancer treatment: a review of new candidate targets. World J Gastroenterol. 2017;23(26):4675–4688. doi:10.3748/wjg.v23.i26.467528765689
   PubMed Web of Science ®Google Scholar
• Vogel A, Hofheinz RD, Kubicka S, Arnold D. Treatment decisions in metastatic colorectal cancer - beyond first and second line combination therapies. Cancer Treat Rev. 2017;59:54–60. doi:10.1016/j.ctrv.2017.04.00728738235
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x30886395
   PubMed Web of Science ®Google Scholar
• Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol. 2020;13:1756284820917527. doi:10.1177/1756284820917527
   Web of Science ®Google Scholar
• Lee JJ, Chu E. Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(4):258–273. doi:10.1016/j.clcc.2018.06.00430072278
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–779. doi:10.1200/JCO.2017.76.990129355075
   PubMed Web of Science ®Google Scholar
• Guo J, Yu Z, Das M, Huang L. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano. 2020;14(4):5075–5089. doi:10.1021/acsnano.0c0167632283007
   PubMed Web of Science ®Google Scholar
• Winer A, Ghatalia P, Bubes N, et al. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with lynch syndrome, metastatic colon, and localized urothelial cancer. Oncologist. 2019;24(11):1416–1419. doi:10.1634/theoncologist.2018-068631444293
   PubMed Web of Science ®Google Scholar
• Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Sci. 2019;110(4):1148–1155. doi:10.1111/cas.1397230742729
   PubMed Web of Science ®Google Scholar
• Morse MA, Hochster H, Benson A. Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy. Oncologist. 2020;25(1):33–45. doi:10.1634/theoncologist.2019-017631383813
   PubMed Web of Science ®Google Scholar
• Lu YC, Jia L, Zheng Z, Tran E, Robbins PF, Rosenberg SA. Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy. Cancer Immunol Res. 2019;7(11):1824–1836. doi:10.1158/2326-6066.CIR-19-029931484655
   PubMed Web of Science ®Google Scholar
• Xiao L, Cen D, Gan H, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019;27(6):1114–1125. doi:10.1016/j.ymthe.2019.03.01130962163
   PubMed Web of Science ®Google Scholar
• Fan J, Shang D, Han B, Song J, Chen H, Yang JM. Adoptive cell transfer: is it a promising immunotherapy for colorectal cancer? Theranostics. 2018;8(20):5784–5800. doi:10.7150/thno.2903530555581
   PubMed Web of Science ®Google Scholar
• Kitsou M, Ayiomamitis GD, Zaravinos A. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. Int J Oncol. 2020;57(1):237–248. doi:10.3892/ijo.2020.506232468013
   PubMed Web of Science ®Google Scholar
• Jiang S, Good D, Wei MQ. Vaccinations for colorectal cancer: progress, strategies, and novel adjuvants. Int J Mol Sci. 2019;20(14):3403. doi:10.3390/ijms20143403
   PubMed Web of Science ®Google Scholar
• Coupez D, Hulo P, Touchefeu Y, Bossard C, Bennouna J. Pembrolizumab for the treatment of colorectal cancer. Expert Opin Biol Ther. 2020;20(3):219–226. doi:10.1080/14712598.2020.171809531952453
   PubMed Web of Science ®Google Scholar
• Ciardiello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019;76:22–32. doi:10.1016/j.ctrv.2019.04.00331079031
   PubMed Web of Science ®Google Scholar
• Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Immunotherapy, inflammation and colorectal cancer. Cells. 2020;9(3):618. doi:10.3390/cells9030618
   PubMed Web of Science ®Google Scholar